Central ethical dilemmas in research involving children

Accountability in Research

Volumn 9, Issue 3-4, 2002, Pages 127-142

  Tauer, Carol A ^a  

^a ST CATHERINE UNIVERSITY   (United States)

Author keywords

Drug testing; Federal research regulations; Pediatric exclusivity; Pediatric rule; Research ethics; Research involving children

Indexed keywords

ADVISORY COMMITTEE; ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; CHILD; ETHICS; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; GOVERNMENT REGULATION; HUMAN; HUMAN EXPERIMENT; LEGAL APPROACH; MEDICAL RESEARCH; PROFESSIONAL STANDARD; RESEARCH ETHICS; RISK ASSESSMENT; STANDARD; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH; LEGAL APPROACH;

ADVISORY COMMITTEES; BIOMEDICAL RESEARCH; CHILD; ETHICS COMMITTEES, RESEARCH; ETHICS, RESEARCH; GOVERNMENT REGULATION; HUMAN EXPERIMENTATION; HUMANS; RISK ASSESSMENT; UNITED STATES; UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0038117616     PISSN: 08989621     EISSN: 15455815     Source Type: Journal    
DOI: 10.1080/08989620214686     Document Type: Article

References (46)

1. American Academy of Pediatrics (AAP) Committee on Drugs (1995). Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 95:286-294.
2. American Academy of Pediatrics, Ambulatory Pediatric Association, American Pediatric Society, Association of Medical School Pediatric Department Chairs, Elizabeth Glaser Pediatric AIDS Foundation, and Society for Pediatric Research (2002). Letter to Tommy Thompson on the pediatric rule, March 22. Available at http://www.aap.org/advocacy/washing/fda%5Fletter.htm
3. Ass'n of Amer. Physicians and Surgeons et al. v. U.S. Food & Drug Admin. (2001). No. 00-02898 (D.D.C., October 25).
4. Best Pharmaceuticals for Children Act (2002). 21 U.S.C. s 505A.
5. Code of Federal Regulations, 45 CFR 46:101-124 (1991). Federal policy for the protection of human subjects. (The Common Rule.) Federal Register 56:28003-28016.
6. Code of Federal Regulations, 45 CFR 46:201-207 (2001). Additional protections for pregnant women, human fetuses and neonates involved in research. (Subpart B.) Federal Register 66:56778-56780.
7. Code of Federal Regulations, 45 CFR 46:401-409 (1983). Additional protections for children involved as subjects in research. (Subpart D.) Federal Register 48:9816-9820.
8. Connolly, C. (2002). FDA to suspend a rule on child drug testing. Washington Post, March 19, p. A10.
9. Consumer Alert, Inc. (1999). FDA's rule challenged. Consumer Comments, December. Available at http://www.consumeralert.org/pubs/comments/NovDec99/FDA.htm.
10. Coté, C. J., Kauffman, R. E., Troendle, G. J., and Lambert, G. H. (1996). Is the "therapeutic orphan" about to be adopted? Pediatrics 98:118-123.
11. Department of Health and Human Services (DHHS) (1981). Final regulations amending basic HHS policy for the protection of human research subjects. Federal Register 46:8366-8391.
12. Food and Drug Administration (FDA) (2001a). Additional safeguards for children in clinical investigations of FDA-regulated products: Interim rule. Federal Register 66:20589-20600.
13. Food and Drug Administration (FDA) (2001b). Frequently asked questions on pediatric exclusivity (505A), the pediatric "rule," and their interaction. Available at http://www.fda.gov/cder/pediatric/faqs.htm
14. Food and Drug Administration (FDA) (1998). Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients: Final rule. Federal Register 63:66631-66672.
15. Grimes V. Kennedy Krieger Institute (2001). 782 A.2d 807 (Md. 2001).
16. Janofsky, B. A., and Starfield, B. (1981). Assessment of risk in research on children. Journal of Pediatrics 98:842-846.
17. Kauffman, R. E. (1994). Scientific issues in biomedical research with children. In M. A. Grodin and L.H. Glantz (eds.), Children as Research Subjects: Science, Ethics, and Law, pp. 29-45. New York: Oxford University Press.
18. Kaufman, M., and Connolly, C. (2002). U.S. backs pediatric tests in reversal on drug safety. Washington Post, April 20, p. A3.
19. Kennedy Krieger Institute (2001). Lead-based paint study fact sheet. Available at http://www.hopkinsmedicine.org/press/2001/SEPTEMBER/leadfactsheet.htm
20. Kopelman, L. M. (2002). Pediatric research regulations under legal scrutiny: Grimes narrows their interpretation. Journal of Law, Medicine & Ethics 30:39-49.
21. Kopelman, L. M. (2000). Children as research subjects: A dilemma. Journal of Medicine and Philosophy 25:745-764.
22. Kopelman, L. M. (1989). When is the risk minimal enough for children to be used as research subjects? In L. M. Kopelman and J. C. Moskop (eds.) Children and Health Care: Moral and Social Issues, pp. 89-99. Dordrecht: Kluwer Academic Publishers.
23. Lascari, A. D. (1981). Risks of research in children. Journal of Pediatrics 98:759-760.
24. Lederer, S. E., and Grodin, M. A. (1994). Historical overview: Pediatric experimentation. In M. A. Grodin and L. H. Glantz (eds.) Children as Research Subjects: Science, Ethics, and Law, pp. 3-25. New York: Oxford University Press.
25. Lueck, S. (2002). FDA to suspend rules for testing drugs on children. Wall Street Journal, March 19, p. B10.
26. Margulies, J. (2002). Bush administration allows research-protections panel to expire. Chronicle of Higher Education, September 18. Available at http://chronicle.com/daily/2002/09/20020918oln.htm
27. Marshall, M. F. (2002). As the pendulum swings: New approach to research with children. Presentation at Friends Research Institute National Ethics Conference, "Ethics of Research with Children," May 6.
28. Morrison, R. (2001). FDA's pediatric rule hurts public health. Competitive Enterprise Institute press release, March. Available at http://www.heartland.org/health/mar01/fda.htm
29. National Bioethics Advisory Commission (2001). Ethical and Policy Issues in Research Involving Human Participants, Vol. I: Report and Recommendations. Bethesda, MD: National Bioethics Advisory Commission.
30. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (1977). Report and Recommendations: Research Involving Children. Washington, DC: Department of Health Education and Welfare (DHEW Publication No. (OS) 77-0004).
31. National Institutes of Health (NIH) (1998). NIH policy and guidelines on the inclusion of children as participants in research involving human subjects, March 6. National Institutes of Health (NIH), Human Subjects Research Advisory Committee (HSRAC) (2000). Minutes, meeting of November 9. Available at http://ohsr.od.nih.gov/HSRACminutes/110900_HSRAC_minutes.htm
32. Nelson, R. M. (2001). Nontherapeutic research, minimal risk, and the Kennedy Krieger lead abatement study. IRB 23, 6:7-11.
33. New York Times Editorial Staff (2002). Sanity on pediatric drug safety. New York Times, April 23, p. A22.
34. Office for Human Research Protections (OHRP) (2001). Letter of determination on protocol number 96-CH-0101, August 15. Available at http://ohrp.osophs.dhhs.gov/detrm_letrs/aug01o.pdf
35. Office for Human Research Protections (OHRP), National Human Research Protections Advisory Committee (NHRPAC) (2002). Transcript of meeting of April 29. Available at http://ohrp.osophs.dhhs.gov/nhrpac/mtg04-02/0429NHR.txt
36. Office for Human Research Protections (OHRP), National Human Research Protections Advisory Committee (NHRPAC) (2000). Transcript of meeting of December 21. Available at http://ohrp.osophs.dhhs.gov/nhrpac/mtg12-00/1221meet.txt
37. Plummer, J. (2000). FDA's pediatric rule restricts access to medicine. Consumers' Research Magazine, May. Available at http://www.consumeralert.org/pubs/research/CRMay00.htm
38. Prentice, E. D., Antonson, D. L., Jameton, A., Graber, B., and Sears, T. (1989). Can children be enrolled in a placebo-controlled randomized clinical trial of synthetic growth hormone? IRB 11, 1:6-10.
39. Reuters (2002). US senators want pediatric test mandate made law. Reuters Health Information, April 18. Available at http://www.reutershealth.com/archive/2002/04/18/eline/links/20020418elin030.htm
40. Roberts, R. (2002). The view from FDA. Presentation at Friends Research Institute National Ethics Conference, "Ethics of Research with Children," May 7.
41. Shamoo, A. E. (2002). Recent examples of ethically questionable research with children. Presentation at Friends Research Institute National Ethics Conference, "Ethics of Research with Children," May 7.
42. Shirkey, H. (1968). Editorial comment: Therapeutic orphans. Journal of Pediatrics 72:119-120.
43. Tauer, C. A. (2000). Human enhancement uses of biotechnology, ethics, human growth hormone. In T.J. Murray and M.J. Mehlman (eds.) Encyclopedia of Ethical, Legal, and Policy Issues in Biotechnology, pp. 491-502. New York: John Wiley & Sons.
44. Tauer, C. A. (1999). Testing drugs in pediatric populations: The FDA mandate. Accountability in Research 7:37-58.
45. Tauer, C. A. (1994). The NIH trials of growth hormone for short stature. IRB 16, 3:1-9.
46. Waxman, H. A., Dingell, J. D., and Brown, S. (2002). Letter to the President on suspending the pediatric rule, March 18. Available at http://www.house.gov/reform/min/pdfs/pdf_recent/pdf.president.pediatric3.18.02.pdf